STAT1d
Lilly expands its Zepbound vial offering, as Hims pulls back on semaglutide
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
FiercePharma19h
With $27B plan to build 4 new plants, Eli Lilly doubles down on US drug manufacturing
Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...
Weight loss drugs for seniors: what to consider
Consumer Reports warns there are important considerations, especially for older adults, before starting these treatments.
Patients struggle with lack of consistent coverage for popular weight-loss drugs
Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...
FiercePharma2d
Lilly banks stockpile of oral GLP-1 drug with potential launch still more than a year away
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Weight-loss drugs are about to get a lot better
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.